Completed PHASE2 INTERVENTIONAL 2-arm NCT00533442

Rapamycin Versus Mycophenolate Mofetil in Kidney-Pancreas Recipients

Tacrolimus and Mycophenolate Mofetil vs Tacrolimus and Sirolimus in SPK, Pancreas After Kidney or Pancreas Transplant Alone

Sponsor: Astellas Pharma Inc

Conditions Type 1 Diabetes

Interventions Mycophenolate Mofetil Rapamycin Steroids Tacrolimus

Updated 8 times since 2017 Last updated: Jun 12, 2017 Started: Sep 30, 2000 Primary completion: May 31, 2016 Completion: May 31, 2016

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE2 trial investigates Type 1 Diabetes and is currently completed. Astellas Pharma Inc leads this study, which shows 8 recorded versions since 2000 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.

Status Flow

Change History

8 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE2
Jul 2024 — Sep 2024 [monthly]

Completed PHASE2
Jan 2023 — Jul 2024 [monthly]

Completed PHASE2
Dec 2022 — Jan 2023 [monthly]

Completed PHASE2
Jan 2021 — Dec 2022 [monthly]

Completed PHASE2

▶ Show 3 earlier versions

Jun 2018 — Jan 2021 [monthly]

Completed PHASE2
Aug 2017 — Jun 2018 [monthly]

Completed PHASE2
Jan 2017 — Aug 2017 [monthly]

Completed PHASE2

First recorded

Sep 2000

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Astellas Pharma Inc
University of Miami

Data source: University of Miami

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Miami, United States